Meeting the Challenge of Eliminating Chronic Hepatitis B Infection
- PMID: 30939846
- PMCID: PMC6523454
- DOI: 10.3390/genes10040260
Meeting the Challenge of Eliminating Chronic Hepatitis B Infection
Abstract
Over 257 million people live with chronic hepatitis B virus (HBV) infection and there is no known cure. The effective preventative vaccine has no impact on existing infection. Despite the existence of drugs which efficiently suppress viral replication, treatment is usually life-long and finite therapies that cure HBV infection are urgently required. However, even if such therapies were available today, it is unlikely they would reach all of those who need it most, due to chronic hepatitis B (CHB) being largely undiagnosed across the globe and to the dire need for health systems promoting access to therapy. Considerable challenges to developing and implementing an effective HBV cure remain. Nonetheless, important advances towards a cure are being made, both in the development of a multitude of new therapeutic agents currently undergoing clinical trials, and through the establishment of a new global initiative dedicated to an HBV cure, ICE-HBV, that is working together with existing organisations to fast-track an HBV cure available to all.
Keywords: HBV cure; ICE-HBV; chronic HBV disease; current clinical trials; persistence; treatment.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Immunotherapy for Chronic Hepatitis B Virus Infection.Gut Liver. 2018 Sep 15;12(5):497-507. doi: 10.5009/gnl17233. Gut Liver. 2018. PMID: 29316747 Free PMC article. Review.
-
Immunopathogenesis of Hepatitis B Virus.J Infect Dis. 2017 Nov 16;216(suppl_8):S765-S770. doi: 10.1093/infdis/jix356. J Infect Dis. 2017. PMID: 29156047
-
HBV cure: why, how, when?Curr Opin Virol. 2016 Jun;18:135-43. doi: 10.1016/j.coviro.2016.06.003. Epub 2016 Jul 19. Curr Opin Virol. 2016. PMID: 27447092 Review.
-
Antibody-mediated immunotherapy against chronic hepatitis B virus infection.Hum Vaccin Immunother. 2017 Aug 3;13(8):1768-1773. doi: 10.1080/21645515.2017.1319021. Epub 2017 May 19. Hum Vaccin Immunother. 2017. PMID: 28521640 Free PMC article.
-
Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.J Infect Dis. 2017 Nov 16;216(suppl_8):S771-S777. doi: 10.1093/infdis/jix355. J Infect Dis. 2017. PMID: 29156046
Cited by
-
Selenium Donor Inhibited Hepatitis B Virus Associated Hepatotoxicity via the Apoptosis and Ferroptosis Pathways.Anal Cell Pathol (Amst). 2023 Aug 30;2023:6681065. doi: 10.1155/2023/6681065. eCollection 2023. Anal Cell Pathol (Amst). 2023. PMID: 37680557 Free PMC article.
-
3,7-Dihydroxytropolones Inhibit Initiation of Hepatitis B Virus Minus-Strand DNA Synthesis.Molecules. 2020 Sep 27;25(19):4434. doi: 10.3390/molecules25194434. Molecules. 2020. PMID: 32992516 Free PMC article.
-
Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo.Gut. 2022 Feb;71(2):372-381. doi: 10.1136/gutjnl-2020-322571. Epub 2021 Jan 28. Gut. 2022. PMID: 33509930 Free PMC article.
-
Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.Lancet Gastroenterol Hepatol. 2022 Sep;7(9):796-829. doi: 10.1016/S2468-1253(22)00124-8. Epub 2022 Jun 21. Lancet Gastroenterol Hepatol. 2022. PMID: 35738290 Free PMC article.
-
Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in vitro and in vivo.Mol Ther Nucleic Acids. 2023 Dec 27;35(1):102112. doi: 10.1016/j.omtn.2023.102112. eCollection 2024 Mar 12. Mol Ther Nucleic Acids. 2023. PMID: 38292874 Free PMC article.
References
-
- World Health Organization Hepatitis B Fact Sheet. [(accessed on 10 December 2018)]; Available online: http://www.who.int/mediacentre/factsheets/fs204/en/
-
- Zeisel M.B., Lucifora J., Mason W.S., Sureau C., Beck J., Levrero M., Kann M., Knolle P.A., Benkirane M., Durantel D., et al. Towards an HBV cure: State-of-the-art and unresolved questions—Report of the ANRS workshop on HBV cure. Gut. 2015;64:1314–1326. doi: 10.1136/gutjnl-2014-308943. - DOI - PubMed
-
- Zoulim F., Testoni B., Lebosse F. Kinetics of intrahepatic covalently closed circular DNA and serum hepatitis B surface antigen during antiviral therapy for chronic hepatitis B: Lessons from experimental and clinical studies. Clin. Gastroenterol. Hepatol. 2013;11:1011–1013. doi: 10.1016/j.cgh.2013.04.010. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources